Clinical Study
Urinary Angiotensinogen Could Be a Prognostic Marker of Renoprotective Effects of Alogliptin in Patients with Type 2 Diabetes
Table 3
Patient profiles partitioned by the cutoff value of UAGTCR before treatments.
| Group | High | Low | value |
| | 20 | 23 | | Men/women | 11/9 | 14/9 | = 0.76 | Age (years) | 67.0 ± 2.5 | 65.4 ± 2.4 | = 0.66 | BMI (kg/m2) | 24.1 ± 0.7 | 25.4 ± 0.7 | = 0.19 | Treatment duration of T2D (years) | 6.9 ± 1.8 | 7.4 ± 1.6 | = 0.82 | Medications | | | | ARB | 12 (60.0%) | 11 (47.8%) | = 0.54 | -GI | 4 (20.0%) | 4 (17.4%) | = 1.00 | TZD | 1 (5.00%) | 4 (17.4%) | = 0.35 |
|
|
ARB: angiotensin II receptor blockers, -GI: -glucosidase inhibitors, and TZD: thiazolidines.
|